Skye Bioscience, Inc. (SKYE) Dividend History

Skye Bioscience, Inc. (SKYE) is a biotechnology company focused on developing cannabinoid-based pharmaceutical products. The company aims to leverage its proprietary formulations and delivery technologies to create targeted therapies for various medical conditions, including glaucoma and other ophthalmic diseases. Skye Bioscience focuses on advancing innovative treatments that utilize cannabinoids to address unmet medical needs.

Dividend History

Skye Bioscience, Inc. currently does not pay dividends

Company News

  • Skye Bioscience to Participate in Upcoming Investment Conferences

    Skye Bioscience, a clinical-stage biotechnology company, announced its participation in upcoming healthcare conferences and a partnership with Arecor Therapeutics to develop an enhanced formulation of its obesity candidate, nimacimab.

    GlobeNewswire Inc.
  • Don't Sleep on Skye Bioscience—This Weight Loss Drug Could Soar

    Skye Bioscience is developing a weight loss drug, nimacimab, that could be an alternative to GLP-1 agonists like those sold by Eli Lilly. Nimacimab aims to reduce the gastrointestinal side effects common with GLP-1 drugs, but may be less effective in inducing weight loss on its own.

    Benzinga
    Featured Companies: LLY
  • 3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn't Ignore

    The article discusses three micro-cap stocks with significant potential and risk: Rent the Runway (RENT), 374Water (SCWO), and Skye Bioscience (SKYE). These companies operate in the clothing rental, wastewater treatment, and pharmaceutical industries, respectively, and have the potential for massive growth but also carry high risks.

    Investing.com
    Featured Companies: RENT SCWO
Page data last updated 07/23/2025 21:11:56 UTC